Showing results (1-10 of 32) with videos related to
Sort By:
Pageof 4
Future Oncology (London, England)|February 17, 2022
PD-1 targeted immunotherapy for advanced hepatocellular carcinoma: current utilization and outcomes in the USAJohannes Uhlig, Stacey Stein, Hyun S KimClinical Colorectal Cancer|July 16, 2010
Treatment paradigms with epidermal growth factor receptor-targeted therapies in colorectal cancerStacey Stein, Deirdre J Cohen, Howard S HochsterFrontiers in Oncology|March 3, 2025
Are all programmed cell death protein 1 inhibitors the same?Jochen H Lorch, Stacey Stein, Martin J EdelmanExperimental Hematology & Oncology|October 10, 2015
Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicityYue Zhang, Howard Hochster, Stacey Stein, et al.JAMA Network Open|January 12, 2021
Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal CancerKishan K Patel, Stacey Stein, Jill Lacy, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 2, 2021
Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer DatabaseJohannes Uhlig, Michael Cecchini, Amar Sheth, et al.Scientific Reports|November 21, 2019
Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular CarcinomaWilliam M Kamp, Cortlandt M Sellers, Stacey Stein, et al.Journal of Vascular and Interventional Radiology : JVIR|May 8, 2020
Direct-Acting Antivirals Improve Overall Survival in Interventional Oncology Patients with Hepatitis C and Hepatocellular CarcinomaWilliam M Kamp, Cortlandt M Sellers, Stacey Stein, et al.Journal of Gastrointestinal Oncology|January 24, 2022
Clinical outcomes of first line FOLFIRINOX vs. gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital SystemTimil Patel, Joseph Miccio, Michael Cecchini, et al.Scientific Reports|December 17, 2024
Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasmsJohannes Uhlig, James Nie, Joanna Gibson, et al.Pageof 4